Kosti P, Opzoomer J, Larios Martinez K, Henley Smith R, Scudamore C, Okesola M, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2021;2:100227 pubmed publisher

DROKHLYANSKY E, Göz Aytürk D, Soh T, Chrenek R, O Loughlin E, Madore C, et al. The brain parenchyma has a type I interferon response that can limit virus spread. Proc Natl Acad Sci U S A. 2017;114:E95-E104 pubmed publisher

Maeda Y, Terasawa H, Tanaka Y, Mitsuura C, Nakashima K, Yusa K, et al. Separate cellular localizations of human T-lymphotropic virus 1 (HTLV-1) Env and glucose transporter type 1 (GLUT1) are required for HTLV-1 Env-mediated fusion and infection. J Virol. 2015;89:502-11 pubmed publisher

Madireddi S, Eun S, Lee S, Nemčovičová I, Mehta A, Zajonc D, et al. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J Exp Med. 2014;211:1433-48 pubmed publisher

Tokarev A, Munguia J, Guatelli J. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol. 2011;85:51-63 pubmed publisher

Zornetzer G, Frieman M, Rosenzweig E, Korth M, Page C, Baric R, et al. Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J Virol. 2010;84:11297-309 pubmed publisher